20.90
price up icon0.19%   0.04
after-market After Hours: 21.31 0.41 +1.96%
loading
Arrivent Biopharma Inc stock is traded at $20.90, with a volume of 192.38K. It is up +0.19% in the last 24 hours and up +6.04% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$20.86
Open:
$20.88
24h Volume:
192.38K
Relative Volume:
0.64
Market Cap:
$847.89M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-5.199
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
+4.76%
1M Performance:
+6.04%
6M Performance:
+15.15%
1Y Performance:
-25.99%
1-Day Range:
Value
$20.49
$21.07
1-Week Range:
Value
$19.15
$21.86
52-Week Range:
Value
$15.47
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Name
Arrivent Biopharma Inc
Name
Phone
240-780-6356
Name
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVBP
Arrivent Biopharma Inc
20.90 846.27M 0 -136.98M -126.63M -4.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Buy
Mar-20-25 Initiated B. Riley Securities Buy
Mar-10-25 Initiated Guggenheim Buy
Jul-22-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Feb-20-24 Initiated Citigroup Buy
Feb-20-24 Initiated Goldman Buy
Feb-20-24 Initiated Jefferies Buy
View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

pulisher
10:40 AM

Why ArriVent BioPharma Inc. stock is favored by pension fundsMarket Risk Analysis & Weekly High Potential Alerts - newser.com

10:40 AM
pulisher
01:32 AM

How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & Free Long-Term Investment Growth Plans - newser.com

01:32 AM
pulisher
Oct 10, 2025

What’s the recovery path for long term holders of ArriVent BioPharma Inc.July 2025 Institutional & Weekly Breakout Watchlists - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Analyzing ArriVent BioPharma Inc. with multi timeframe chartsJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN

Oct 08, 2025
pulisher
Oct 06, 2025

Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 06, 2025
pulisher
Oct 05, 2025

Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com

Oct 03, 2025
pulisher
Sep 30, 2025

Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener

Sep 30, 2025
pulisher
Sep 30, 2025

Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener

Sep 30, 2025
pulisher
Sep 29, 2025

ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo

Sep 29, 2025
pulisher
Sep 27, 2025

ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN

Sep 27, 2025
pulisher
Sep 26, 2025

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN

Sep 26, 2025
pulisher
Sep 26, 2025

Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com

Sep 26, 2025
pulisher
Sep 25, 2025

Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com

Sep 25, 2025
pulisher
Sep 23, 2025

Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com

Sep 23, 2025
pulisher
Sep 23, 2025

Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks

Sep 22, 2025
pulisher
Sep 22, 2025

Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

Oncology Biotech ArriVent BioPharma Taps 25-Year Industry Veteran to Lead Lung Cancer Drug Launch - Stock Titan

Sep 22, 2025
pulisher
Sep 22, 2025

Will earnings trigger a reversal in ArriVent BioPharma Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Institutional scanner results for Baker Hughes CompanyTrade Signal Summary & Daily Technical Forecast Reports - newser.com

Sep 22, 2025

Arrivent Biopharma Inc Stock (AVBP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):